terzepitide vs semaglutide GLP 1 flowchart breakdown 101 💉 Tirzepatide Semaglutide vs Terzepitide Allen TX

The addressable market for Wegovy and similar GLP-1 drugs is premium-priced and large

The expected arrival of generics follows the apparent lapse in Novo Nordisks Canadian patent, which the company last maintained in 2018, according to a Science report

The researchers found a lower rate of adverse clinical events in the GLP-1 treated group

10.1016/s0140-6736(19)31271-1 64 RamracheyaR.ChapmanC.ChibalinaM.DouH.MirandaC.GonzlezA.et al (2018)

Net result: only -5.6% from baseline at month 120 vs -17.3% at peak

In adults with overweight or obesity (without diabetes) the semaglutide 2.4 mg dose produced an average weight reduction of about 15% of baseline body weight over ~68 weeks in the STEP 1 trial, a result that surprised many clinicians because it brought pharmacologic outcomes into a range previously associated with surgical interventions